We provide you with 20 years of free, institutional-grade data for JNCE stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of JNCE. Explore the full financial landscape of JNCE stock.
| Reported Date | CIK | Ticker | Type |
|---|
Jounce Therapeutics, Inc(NASDAQ:JNCE) 
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on...
Website: http://www.jouncetx.com
Founded: 2012
Full Time Employees: 129
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about JNCE stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.